205 related articles for article (PubMed ID: 28969629)
1. Decision support systems for incurable non-small cell lung cancer: a systematic review.
Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; Jansma EP; De Vet HCW; Coupé VMH
BMC Med Inform Decis Mak; 2017 Oct; 17(1):144. PubMed ID: 28969629
[TBL] [Abstract][Full Text] [Related]
2. Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.
Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; de Vet HCW; Coupé VMH
J Cancer Educ; 2020 Apr; 35(2):345-351. PubMed ID: 30685832
[TBL] [Abstract][Full Text] [Related]
3. Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review.
Engelhardt EG; Révész D; Tamminga HJ; Punt CJA; Koopman M; Onwuteaka-Philipsen BD; Steyerberg EW; Jansma IP; De Vet HCW; Coupé VMH
Clin Colorectal Cancer; 2018 Mar; 17(1):e1-e12. PubMed ID: 28734786
[TBL] [Abstract][Full Text] [Related]
4. Rapid learning in practice: a lung cancer survival decision support system in routine patient care data.
Dekker A; Vinod S; Holloway L; Oberije C; George A; Goozee G; Delaney GP; Lambin P; Thwaites D
Radiother Oncol; 2014 Oct; 113(1):47-53. PubMed ID: 25241994
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
Vickers AD; Winfree KB; Cuyun Carter G; Kiiskinen U; Jen MH; Stull D; Kaye JA; Carbone DP
BMC Cancer; 2019 Apr; 19(1):353. PubMed ID: 30987609
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
[TBL] [Abstract][Full Text] [Related]
7. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
[TBL] [Abstract][Full Text] [Related]
8. Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer.
Engelhardt EG; Révész D; Tamminga HJ; Punt CJA; Koopman M; Onwuteaka-Philipsen BD; Steyerberg EW; de Vet HCW; Coupé VMH
BMC Med Inform Decis Mak; 2018 Dec; 18(1):132. PubMed ID: 30551735
[TBL] [Abstract][Full Text] [Related]
9. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.
Stevens R; Macbeth F; Toy E; Coles B; Lester JF
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD002143. PubMed ID: 25586198
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
[TBL] [Abstract][Full Text] [Related]
11. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
Gutiérrez L; Royuela A; Carcereny E; López-Castro R; Rodríguez-Abreu D; Massuti B; González-Larriba JL; García-Campelo R; Bosch-Barrera J; Guirado M; Camps C; Dómine M; Bernabé R; Casal J; Oramas J; Ortega AL; Sala MA; Padilla A; Aguiar D; Juan-Vidal O; Blanco R; Del Barco E; Martínez-Banaclocha N; Benítez G; de Vega B; Hernández A; Saigi M; Franco F; Provencio M
BMC Cancer; 2021 Aug; 21(1):977. PubMed ID: 34465283
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
[TBL] [Abstract][Full Text] [Related]
14. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.
Jackman DM; Zhang Y; Dalby C; Nguyen T; Nagle J; Lydon CA; Rabin MS; McNiff KK; Fraile B; Jacobson JO
J Oncol Pract; 2017 Apr; 13(4):e346-e352. PubMed ID: 28260402
[TBL] [Abstract][Full Text] [Related]
15. External Validation of a Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer.
Nieder C; Tollåli T; Haukland E; Reigstad A; Flatøy LR; Dalhaug A
Clin Lung Cancer; 2017 Jul; 18(4):e297-e301. PubMed ID: 28189593
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
17. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
18. Primary therapeutic decision-making in inoperable non-small cell lung cancer.
Erkurt E; Tunali C; Erkişi M
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):439-44. PubMed ID: 10661352
[TBL] [Abstract][Full Text] [Related]
19. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
Al-Shamsi HO; Al Farsi A; Ellis PM
Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
